I totally agree re 2022 cashflow positive forecast and for the CEO to be so definitive about it at the AGM makes me wonder what is the game changer.
There is no way testosterone sales will bridge the 11.4 mil cashflow gap and our spending increases as we get more developments to CMO/CRO stage. EMLA, despite the Harris hiccup (Dobinson probably signed that one) is no more that a parma and a beer at the local.
I still think back the CEO and his team
ACR Price at posting:
10.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)